HBV antisense inhibitors

Details for Australian Patent Application No. 2010306639 (hide)

Owner Glaxo Group Limited

Inventors Hamatake, Robert

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2010306639

PCT Pub. Number WO2011/047312

Priority 61/252,380 16.10.09 US

Filing date 15 October 2010

Wipo publication date 21 April 2011

International Classifications

A61K 31/7115 (2006.01) - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine

A61K 31/7125 (2006.01) - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

Event Publications

31 May 2012 PCT application entered the National Phase

  PCT publication WO2011/047312 Priority application(s): WO2011/047312

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010306645-Supercoiled minicircle DNA for gene therapy applications

2010306638-Hinge mechanism for a fluid filled lens assembly